
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx Inc demonstrated impressive financial performance with a 32% year-over-year revenue growth in 4Q24, reaching $86.6 million, and an overall annual revenue growth of 19% in 2024, with projections of 17% growth for 2025. The company is experiencing increasing testing volumes, evidenced by a 14% rise in volume from 4Q23 to 4Q24, and is strategically focused on achieving a long-term revenue target of $500 million by 2027. Key growth initiatives, including expanding payer coverage and enhancing operational excellence, position CareDx for sustained momentum in the precision medicine sector, particularly within the transplant community.
Bears say
CareDx Inc faces significant financial risks that contribute to a negative outlook for its stock. Key concerns include the potential inability to secure adequate reimbursement for its testing services, competition from superior tests developed by rivals, and integration challenges from acquisitions that could disrupt business operations. Additionally, the company's EBITDA guidance fell short of expectations, further highlighting uncertainties around the commercial success of its products and the broader implications of compliance with evolving healthcare policies.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares